Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04576156 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
A Phase 3 study of Myelofibrosis, sponsored by Geron Corporation.
- Active
- Registry status
- Phase 3
- Development phase
- 327
- Enrollment target
- 20
- Study locations
NCT04576156: Active Phase 3 study of Myelofibrosis, sponsored by Geron Corporation.
NCT04576156 is a Phase 3 study of Myelofibrosis that is active but no longer recruiting, run by Geron Corporation. The registered enrollment target is 327 participants, above the 191-participant average among 61 other Myelofibrosis trials with a reported enrollment target (71% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04576156, a Phase 3 study of Myelofibrosis, is active but no longer recruiting, sponsored by Geron Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 327 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
Primary Outcome
Overall survival is defined as the time interval from randomization date to date of death from any cause.
Conditions Studied
Interventions
- DRUG Imetelstat
- DRUG Best Available Therapy (BAT)
Study Locations (20)
California
- University of California-San Diego/Moores UCSD Cancer Center - La Jolla
- UCLA David Geffen School of Medicine - Los Angeles
Florida
- BRCR Medical Center Inc - Plantation
- University of South Florida - Tampa
Texas
- Oncology Consultants - Houston
- The University of Texas MD - Houston
Utah
- Community Cancer Trials of Utah - Ogden
- Utah Cancer Specialists - Salt Lake City
Connecticut
- Smilow Cancer Center at YNHH - New Haven
Kentucky
- Norton Cancer Institute - Louisville
Louisiana
- Ochsner Clinic Foundation - New Orleans
Maryland
- Maryland Oncology Hematology - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2021-04-12 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 3 |
What the registry record for NCT04576156 still lists
NCT04576156 is an interventional study that assigns participants to a tested intervention. The registered 327 participants enrollment target is mid-sized for trials with a published cap, above the 191-participant average among 61 other Myelofibrosis trials with a reported enrollment target (71% higher).
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which Imetelstat is the first listed.
NCT04576156 names 20 study sites across 16 states, led by California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT04576156 about?
NCT04576156 is a clinical study titled "A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment". The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
What is the current status of trial NCT04576156?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 327 participants. The study started on 2021-04-12. Estimated completion is 2028-06-30.
What conditions does trial NCT04576156 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT04576156?
The interventions under investigation include: Imetelstat (DRUG), Best Available Therapy (BAT) (DRUG).
Who is sponsoring clinical trial NCT04576156?
This trial is sponsored by Geron Corporation, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04576156 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04576156's enrollment target sits among peer trials
327 7th of 61 higher than 55 of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
RECRUITING · Phase 3
-
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
RECRUITING · Phase 3
-
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
ACTIVE NOT RECRUITING · Phase 3
-
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486378 · 327 participants · Phase 2
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
- NCT06370182 · 327 participants · NA
Safety and Effectiveness of Mechanical Thrombectomy Using the Anaconda ANA Funnel Catheter
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05380401 · 328 participants · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI